Back to Journals » Clinical Ophthalmology » Volume 11

Immediate sequential bilateral intravitreal injections: an Indian perspective

Authors Tripathy K

Received 27 February 2017

Accepted for publication 28 February 2017

Published 6 April 2017 Volume 2017:11 Pages 639—640

DOI https://doi.org/10.2147/OPTH.S135685

Checked for plagiarism Yes

Editor who approved publication: Dr Scott Fraser

Koushik Tripathy

Department of Vitreoretina and Uvea, ICARE Eye Hospital and Postgraduate Institute, Sector-26, Noida, Uttar Pradesh, India

Recently, Ruão et al1 have shown in a study spanning 6 years that only 1 of 6560 (0.015%) eyes undergoing unilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection developed culture-proven endophthalmitis. None of the 1612 eyes receiving immediate sequential bilateral intravitreal treatment (ISBIVT) with anti-VEGF injection developed endophthalmitis.1 Likewise, immediate sequential bilateral cataract surgery (ISBCS)2 has been proposed to provide “potentially decreased wait times for surgery, patient convenience and cost savings for health care payors”, with comparable visual outcomes and complication rates. However, in an Indian scenario, there is need for discussion regarding endophthalmitis following ISBIVT injections.

View the original paper by Ruão and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author: